← Leaderboards
Kangmo Lu
Charlesson, Llp
$1,672,720
Attributed
$1,672,720
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $570.4K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,672,720 · 4
By mechanism
R43$1,672,720 · 4
Top collaborators
No co-investigators on record.
Most similar at Charlesson, Llp
Same institution · by research overlap
- Rafal A Farjo$4,717,138
- Yan Feng$100,000
- Danyang Chen$3,659,618
Others in their field
Top investigators on “Adult”
- Lawrence Corey · Fred Hutchinson Cancer Center$594,628,824
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$397,114,680
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$388,038,550
- Judith S. Currier · University Of California Los Angeles$251,592,913
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$196,603,707
- Carol Nesel · Westat$188,148,170
Research focus
AdultAlbuminsAmericanAmino AcidsAngiogenesisAngiogenesis InhibitorsAngiogenic FactorAngiostatinsAnimal ModelAttenuatedBaseBlindnessBlood-Retinal BarrierBlood VesselsBlotting, WesternBos TaurusCattleCell MotilityCell ProliferationCellsCell TypeChitosanCitiesAbbreviations
Grant awards (5)
Nanotechnology for Treatment of Diabetic Retinopathy$570,438
R43 · FY2008 · EY · contact PI
Nanotechnology for Treatment of Diabetic Retinopathy$570,438
R43 · FY2007 · EY · contact PI
Novel Linomide Analog for Treatment of Diabetic Retinopathy$248,294
R43 · FY2006 · EY · contact PI
New Thalidomide Analogs for Retinal Neovacularization$149,800
R43 · FY2005 · EY
Peptide Eyedrops for Treatment of Diabetic Retinopathy$133,750
R43 · FY2005 · EY